pharma · Breast Cancer · Prostate Cancer · UTHR
United Therapeutics Europe
United Therapeutics Europe Ltd
United Therapeutics Europe clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1000 Spring Street, Silver Spring, Maryland 20910, US
- Founded
- 1996
- Employees
- 1,443
- Programs
- 25
- Drugs
- 509
- Patents
- 90
United Therapeutics Europe projects
7 ClinicalTrials.gov programs sponsored by United Therapeutics Europe.
United Therapeutics Europe has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Biospecimen Collection
United Therapeutics Europe Ltd
Glioma
1 trial -
D/ChAd63-CA
United Therapeutics Europe Ltd
Malaria
1 trial -
FMP012 with AS01B adjuvant system
United Therapeutics Europe Ltd
Malaria
1 trial -
FMP1/AS02A
United Therapeutics Europe Ltd
Malaria
1 trial -
Group 1: 10 ug FMP012 with 2 ug GLA-SE
United Therapeutics Europe Ltd
Malaria
1 trial -
Plasmodium falciparum Malaria Protein 010 (FMP010)
United Therapeutics Europe Ltd
Malaria
1 trial -
treatment A
United Therapeutics Europe Ltd
Dyslipidemia
1 trial
Frequently asked questions
How many clinical projects does United Therapeutics Europe have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.